Month: January 2026

Investigational ARC-BCI® Therapy is being developed to restore thought-driven movement in people living with spinal cord injuries and other movement disabilities ARC-BCI is the world’s first and most advanced purpose-designed platform pairing a brain-computer interface with an implantable spinal cord stimulation system Seven study participants have now received ARC-BCI Therapy to restore movement of their own paralyzed limbsEINDHOVEN, the Netherlands, Jan. 22, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, announces that two additional individuals living with spinal cord injuries (SCI) have received the Company’s investigational ARC-BCI® Therapy. These groundbreaking procedures...

Tryg’s Supervisory Board has today approved the annual report for 2025. Tryg reported an insurance service result of DKK 7,945m (DKK 7,056m) and a combined ratio of 80.3% (81.7%) in 2025. The higher insurance service result was supported by the profitability turnaround in Norway, a growth of 3.8% (4.1%) in local currencies, and a continued underlying profitability improvement. The investment result was at DKK 778m (DKK 911m). Pre-tax profit was DKK 7,212m (DKK 6,303m) and profit after tax was DKK 5,405m (DKK 4,816m). Ordinary dividend of DKK 8.20 (DKK 7.80) per share for the year is an increase of more than 5% from the previous year. In addition, a share buyback programme of DKK 1bn is launched and expected to be concluded no later than 13 May 2026. With this, the reported solvency ratio at the end of 2025 was 196% (204% Q3 2025), supportive...

Sampo plc, stock exchange release, 22 January 2026 at 8:30 am EET Sampo plc’s share buybacks 21 January 2026 On 21 January 2026, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  13,276 9.84 AQEU    138,883 9.83 CEUX  39,813 9.83 TQEX  193,991 9.83 XHELTOTAL 385,963 9.83  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November...

Ipsos unveils Horizons, its transformation and growth strategy to reinforce its global leadership Paris, January 22nd, 2026 – Ipsos, one of the world’s leading market research and opinion polling companies, today presents at its Investor Day its new strategic plan, to return to a sustained pace of growth. This strategy, led by CEO Jean Laurent Poitou and approved by the entire Board of Directors, sets out the company’s new ambitions and its execution plan. The annual organic growth rate is expected to reach 5% or more in 2028, accompanied by an improvement in the operating margin, which should reach a record level of 13.5% in that same year. Ipsos’ strategy relies on six pillars:  1.   Harnessing the full potential of its broad range of services Ipsos’ multi-specialist model allows it to offer solutions that...

The share buyback programme is launched with reference to the authorisation to acquire treasury shares granted by the general meeting on 26 March 2025. The authorisation is valid until 31 December 2026 and allows Tryg to acquire shares with a total nominal value of up to DKK 300,000,000 corresponding to app. 10% of its share capital. The share buyback programme will start on 22 January 2026 and end no later than 13 May 2026. The share buyback programme will be executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). Tryg has appointed Danske Bank A/S as lead manager of the share buyback programme. Under a separate agreement, Danske Bank A/S will within the announced limits buy...

Tryg Forsikring’s full Annual report for 2025 will be published 5 February 2026Annual report 2025 for the entire Tryg Group is available on Tryg.com. Tryg Forsikring reported an insurance service result of DKK 7,945m (DKK 7,056m) and a combined ratio of 80.3% (81.7%) in 2025. The higher insurance service result was supported by the profitability turnaround in Norway, a growth of 3.8% (4.1%) in local currencies, and a continued underlying profitability improvement. The investment result was at DKK 757m (DKK 910m). Pre-tax profit was DKK 7,320m (DKK 6,423m) and profit after tax was DKK 5,495m (DKK 4,911m). Solvency ratio at the end of 2025 was 196% (202% H1 2025). Financial highlights 2025Insurance revenue growth of 3.8% in local currencies (4.1%) Insurance service result of DKK 7,945m (DKK 7,056m) Combined ratio of 80.3% (81.7%) Expense...

ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Axogen from the proposed offering, before deducting underwriters’ discounts and commissions and other offering...

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. All of the shares of common stock are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,185,101 shares of common stock at the public offering price, less underwriting discounts and commissions. Corvus currently expects to use the net proceeds from this...

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional...